Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $75.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by The Goldman Sachs Group from $60.00 to $75.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

KNSA has been the topic of several other research reports. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and an average target price of $68.00.

Kiniksa Pharmaceuticals International Trading Down 0.3%

Kiniksa Pharmaceuticals International stock opened at $62.84 on Thursday. The company has a market capitalization of $4.83 billion, a price-to-earnings ratio of 69.82 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 12 month low of $26.27 and a 12 month high of $67.53. The stock’s 50 day moving average is $56.87 and its 200-day moving average is $49.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $0.11 EPS. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 628,427 shares of company stock valued at $32,833,228 in the last three months. Corporate insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Amundi bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares during the period. Millennium Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the period. Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $358,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $43,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.